Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Andrea Chiricozzi, Anna Balato, Curdin Conrad, Andrea Conti, Paolo Dapavo, Paulo Ferreira, Francesca Maria Gaiani, Luiz Leite, Piergiorgio Malagoli, Pedro Mendes-Bastos, Matteo Megna, Francesco Messina, Alessia Nidegger, Giulia Odorici, Salvatore Panduri, Stefano Piaserico, Leonardo Piscitelli, Francesca Prignano, Simone Ribero, Joana Valerio & Tiago Torres. (2020) Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study. Journal of Dermatological Treatment 31:5, pages 476-483.
Read now
Read now
Daniel Wendling, Frank Verhoeven & Clément Prati. (2019) Anti-IL-17 monoclonal antibodies for the treatment of ankylosing spondylitis. Expert Opinion on Biological Therapy 19:1, pages 55-64.
Read now
Read now
Claudia Lasagni, Laura Bigi, Andrea Conti & Giovanni Pellacani. (2018) Successful therapy of plaque-type psoriasis with secukinumab in patients with multiple comorbidities treated with previous biologic therapies. Journal of Dermatological Treatment 29:sup2, pages 5-8.
Read now
Read now
Tessa L Hanley & Zenas ZN Yiu. (2017) Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab. Therapeutics and Clinical Risk Management 13, pages 315-323.
Read now
Read now
Sunil Dogra, Shraddha Uprety & Swaroop Hassan Suresh. (2017) Itolizumab, a novel anti-CD6 monoclonal antibody: a safe and efficacious biologic agent for management of psoriasis. Expert Opinion on Biological Therapy 17:3, pages 395-402.
Read now
Read now
Rayford R. June & Nancy J. Olsen. (2016) Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis. Expert Opinion on Biological Therapy 16:10, pages 1303-1309.
Read now
Read now
Articles from other publishers (12)
Yun-Zhu Yao, Zhi-Kai Liao, Shan Jiang, Bing-Qi Dong, Long-Fei Luo, Fang Miao & Tie-Chi Lei. (2022) Uncoupling melanogenesis from proliferation in epidermal melanocytes responding to stimulation with psoriasis-related proinflammatory cytokines. Journal of Dermatological Science 108:2, pages 98-108.
Crossref
Crossref
Ruth Rodríguez-Montaño, Alondra del Carmen Ruiz-Gutiérrez, Vianeth María del Carmen Martínez-Rodríguez, Juan Ramón Gómez-Sandoval, Juan Manuel Guzmán-Flores, Julieta Sarai Becerra-Ruiz, Ana Lourdes Zamora-Perez & Celia Guerrero-Velázquez. (2022) Levels of IL-23/IL-17 Axis in Plasma and Gingival Tissue of Periodontitis Patients According to the New Classification. Applied Sciences 12:16, pages 8051.
Crossref
Crossref
Danyi Zhang, Jianing Qiu, Xing Liao, Yi Xiao, Minxue Shen, Yaxiong Deng & Danrong Jing. (2022) Comparison of Efficacy of Anti-interleukin-17 in the Treatment of Psoriasis Between Caucasians and Asians: A Systematic Review and Meta-Analysis. Frontiers in Medicine 8.
Crossref
Crossref
Olivier Lortholary, Mario Fernandez-Ruiz, John W Baddley, Oriol Manuel, Xavier Mariette & Kevin L Winthrop. (2020) Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and biological therapies: a viewpoint in 2020. Annals of the Rheumatic Diseases 79:12, pages 1532-1543.
Crossref
Crossref
K.L. Winthrop, X. Mariette, J.T. Silva, E. Benamu, L.H. Calabrese, A. Dumusc, J.S. Smolen, J.M. Aguado & M. Fernández-Ruiz. (2018) ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clinical Microbiology and Infection 24, pages S21-S40.
Crossref
Crossref
Lipeng Tang, Xiaozhi Yang, Yongxin Liang, Hesong Xie, Zhenhua Dai & Guangjuan Zheng. (2018) Transcription Factor Retinoid-Related Orphan Receptor γt: A Promising Target for the Treatment of Psoriasis. Frontiers in Immunology 9.
Crossref
Crossref
Iris M. Otani, Amy S. Levin & Aleena Banerji. (2018) Cutaneous Manifestations of Reactions to Biologics. Current Allergy and Asthma Reports 18:2.
Crossref
Crossref
Jennifer Beecker & Jiyeh Joo. (2017) Treatment of Moderate to Severe Psoriasis With High-Dose (450-mg) Secukinumab: Case Reports of Off-Label Use. Journal of Cutaneous Medicine and Surgery 22:1, pages 86-88.
Crossref
Crossref
Masaru Ishii. (2017) Immunology proves a great success for treating systemic autoimmune diseases - a perspective on immunopharmacology: IUPHAR Review 23. British Journal of Pharmacology 174:13, pages 1875-1880.
Crossref
Crossref
Adriane A Levin & Jeffrey M Sobell. (2017) Update on IL-17 Inhibitors for Psoriasis. Current Dermatology Reports 6:2, pages 121-128.
Crossref
Crossref
Lazaros I. Sakkas & Dimitrios P. Bogdanos. (2017) Are psoriasis and psoriatic arthritis the same disease? The IL-23/IL-17 axis data. Autoimmunity Reviews 16:1, pages 10-15.
Crossref
Crossref
Byung-Seok Kim, Young-Jun Park & Yeonseok Chung. (2016) Targeting IL-17 in autoimmunity and inflammation. Archives of Pharmacal Research 39:11, pages 1537-1547.
Crossref
Crossref